1. Volume 74, Issue 5, Pages 641-648 (September 2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women 
Steven Boonen, Deborah E. Sellmeyer, Kurt Lippuner, Alexander Orlov-Morozov, Ken Abrams, Peter Mesenbrink, Erik F. Eriksen, Paul D. Miller 
Kidney International 
Volume 74, Issue 5, Pages (September 2008)
DOI: /ki
Copyright © 2008 International Society of Nephrology Terms and Conditions

2. Figure 1
Mean serum creatinine levels from baseline to 36 months in patients with pre- to post-infusion change of >0.5mg/100ml. For each infusion, the patients treated with 5mg of zoledronic acid showed similar mean serum creatinine levels at 9–11 days post-infusion and also at 12 months post-infusion.
Kidney International  , DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

3. Figure 2
Long-term renal safety: mean change in estimated creatinine clearance from baseline to 36 months (safety population). At month 36, the mean (±s.e.m.) decrease from baseline in estimated creatinine clearance was similar in the patients treated with 5mg of zoledronic acid (−8.75±0.175ml/min) and in the placebo group (−8.67±0.175ml/min).
Kidney International  , DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

4. Figure 3
Renal safety monitoring schedule during the HORIZON-PFT study.
Kidney International  , DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions